奥希替尼通过双靶向ALK和EGFR克服由双调蛋白介导的软脑膜癌病模型中对阿来替尼的耐药
本研究在ALK重排NSCLC软脑膜癌病小鼠模型中诱导阿来替尼耐药,发现耐药由miR-449a下调致双调蛋白(AREG)过表达、EGFR激活所致;阿来替尼联合EGFR-TKI(厄洛替尼或奥希替尼)可控制LMC进展;患者脑脊液中AREG在阿来替尼耐药LMC中显著升高。
要点
- AREG过表达通过激活EGFR介导ALK重排NSCLC对阿来替尼的耐药。
- 阿来替尼联合EGFR-TKI在LMC模型中有效控制进展。
- 脑脊液AREG或可提示阿来替尼耐药的LMC。
核心结论
- 靶向ALK和EGFR的双重治疗可能克服ALK重排NSCLC中ALK-TKI耐药的LMC。
研究设计与样本
- 研究在ALK重排NSCLC细胞系A925LPE3构建的LMC小鼠模型中持续口服阿来替尼诱导耐药,建立A925L/AR细胞。
- 采用Western blot和受体酪氨酸激酶阵列等分析耐药机制。
- 用ELISA检测ALK重排NSCLC伴阿来替尼难治性LMC患者脑脊液AREG浓度,并与EGFR突变NSCLC伴EGFR-TKI耐药LMC患者及无LMC患者比较。
主要发现
- A925L/AR细胞在体外对阿来替尼、克唑替尼、色瑞替尼和劳拉替尼等ALK-TKI呈中度耐药。
- A925L/AR细胞因microRNA-449a表达下降导致AREG过表达,进而激活EGFR获得耐药。
- EGFR-TKI和抗EGFR抗体在体外使A925L/AR细胞对阿来替尼重新敏感。
- 在A925L/AR细胞的LMC模型中,阿来替尼联合厄洛替尼或奥希替尼成功控制LMC进展。
- 质谱成像显示EGFR-TKI在肿瘤病灶中蓄积。
临床怎么用
- 对于ALK重排NSCLC患者阿来替尼治疗中出现LMC进展,可考虑联合EGFR-TKI(如厄洛替尼或奥希替尼)靶向AREG-EGFR通路。
- 脑脊液AREG检测可能有助于识别阿来替尼耐药LMC患者,指导联合治疗决策。
局限性
- 耐药机制和联合治疗主要基于临床前LMC小鼠模型和细胞系。
- 脑脊液AREG比较分析中阿来替尼耐药LMC患者样本量较小(n=4)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Leptomeningeal carcinomatosis (LMC) occurs frequently in anaplastic lymphoma kinase (ALK)-rearranged NSCLC and develops acquired resistance to ALK tyrosine kinase inhibitors (ALK TKIs). This study aimed to clarify the resistance mechanism to alectinib, a second-generation ALK TKI, in LMC and test a novel therapeutic strategy. METHODS: We induced alectinib resistance in an LMC mouse model with ALK-rearranged NSCLC cell line, A925LPE3, by continuous oral alectinib treatment, established A925L/AR cells. Resistance mechanisms were analyzed using several assays, including Western blot and receptor tyrosine kinase array. We also measured amphiregulin (AREG) concentrations in cerebrospinal fluid from patients with ALK-rearranged NSCLC with alectinib-refractory LMC by enzyme-linked immunosorbent assay. RESULTS: A925L/AR cells were moderately resistant to various ALK TKIs, such as alectinib, crizotinib, ceritinib, and lorlatinib, compared with parental cells in vitro. A925L/AR cells acquired the resistance by EGFR activation resulting from AREG overexpression caused by decreased expression of microRNA-449a. EGFR TKIs and anti-EGFR antibody resensitized A925L/AR cells to alectinib in vitro. In the LMC model with A925L/AR cells, combined treatment with alectinib and EGFR TKIs, such as erlotinib and osimertinib, successfully controlled progression of LMC. Mass spectrometry imaging showed accumulation of the EGFR TKIs in the tumor lesions. Moreover, notably higher AREG levels were detected in cerebrospinal fluid of patients with alectinib-resistant ALK-rearranged NSCLC with LMC (n = 4), compared with patients with EGFR-mutated NSCLC with EGFR TKI-resistant LMC (n = 30), or patients without LMC (n = 24). CONCLUSIONS: These findings indicate the potential of novel therapies targeting both ALK and EGFR for the treatment of ALK TKI-resistant LMC in ALK-rearranged NSCLC.
引用
- Arai S, Takeuchi S, Fukuda K, et al. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. J Thorac Oncol. 2020. PMID: 31972351. doi:10.1016/j.jtho.2020.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。